Enochian Biosciences, Inc. (ENOB) stock announced the acquisition of an exclusive license for innovative technology in order to fight against various variants that cause coronavirus as well as influenza after which the ENOB stock price happened to green and saw a push of 10.86% a share as of this writing. The stock was down in the previous trading session and dropped by 1.86% at closing. Let’s check out more about the ENOB stock.

What’s Happening?

Dr. Serhat Gumrukçu developed the novel treatment in which the part of the virus is tricked in order to treat the infection at a rapid rate and protect all kinds of future variants of COVID-19 and influenza as well. This treatment could be effective for longer periods due to the large living time span of 20 months by target viruses cell in human airways. The tricked part of the virus is similar to all SARS-CoV-2 variants as well as COVID-19 viruses that affect humans and also have the same origin as all influenza viruses since 1918. Enochian Biosciences will submit the Pre-Investigator New Drug meeting request for COVID-19 treatment to the U.S Food and Drug Administration near in the future.

The roll-out of vaccines around the globe has fortunately lessened the impact of COVID-19 but there are chances of mutation that could escape from the effect of current vaccines. Furthermore, there is a lot of effort is required to provide easy and effective treatment to cope with this pandemic. The potential treatment discussed above has the potential to stop the current pandemic effect as well as to prevent future variants of COVID-19 along with the influenza virus.

Development in HIV:

The ENOB’s licensed proprietary technology intended for the treatment of HIV in individuals via a cell therapy is moving close to the FDA approval as the FDA has accepted the pre-IND meeting request which would enable the Director of the Seraph Research Institute (SRI), Dr. Serhat Gumrukcu and his team to present the HIV cell therapy to FDA. This innovative cellular therapy could prove to be a functional cure for patients suffering from HIV and would allow them to stop the conventional antiviral treatment for longer periods.

Conclusion:

ENOB stock is climbing today as the investors are responding positively to the acquisition of the exclusive license for potential coronavirus and influenza inhaled treatment and prevention technology. The stock is progressing in its mission to treat patients suffering from HIV via innovative cellular therapy. In short, ENOB stock can be a good bet for investors in the long run.